Misplaced Pages

Zastaprazan: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 18:57, 23 December 2024 editInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,049 edits new page  Latest revision as of 13:57, 31 December 2024 edit undoInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,049 editsNo edit summary 
(8 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
| drug_name = | drug_name =
Line 50: Line 51:
| synonyms = JP-1366 | synonyms = JP-1366
| CAS_number = 2133852-18-1 | CAS_number = 2133852-18-1
| ChemSpiderID = 115007138
| PubChem = 138622158 | PubChem = 138622158
| UNII = W9S9KZX5MD | UNII = W9S9KZX5MD
| DrugBank = | DrugBank =
<!-- Chemical and physical data --> <!-- Chemical and physical data -->
| IUPAC_name = azetidin-1-yl--2,3-dimethylimidazopyridin-6-yl]methanone
| IUPAC_name =
| C = 22 | H = 26 | N = 4 | O = 1 | C = 22 | H = 26 | N = 4 | O = 1
| StdInChI=1S/C22H26N4O/c1-14-7-5-8-15(2)19(14)12-23-20-11-18(22(27)25-9-6-10-25)13-26-17(4)16(3)24-21(20)26/h5,7-8,11,13,23H,6,9-10,12H2,1-4H3
| StdInChIKey = FEQFUBYYZYQTOJ-UHFFFAOYSA-N
| smiles = CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4 | smiles = CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4
}} }}


'''Zastaprazan''' (trade name '''Jaqbo''') is a pharmaceutical drug for gastrointestinal disorders. It is classified as a ].<ref>{{cite journal | doi = 10.1002/psp4.13228 }}</ref><ref>{{cite journal | doi = 10.1080/17425255.2024.2397433 }}</ref> In April 2024, it was approved for use in South Korea for the treatment of erosive ] (GERD).<ref>{{Cite journal | doi = 10.1007/s40265-024-02057-w }}</ref> In addition, it is Phase III clinical trials for ] and ].<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800044958 | title = Zastaprazan | publisher = AdisInsight }}</ref> '''Zastaprazan''' (trade name '''Jaqbo''') is a pharmaceutical drug for gastrointestinal disorders. It is classified as a ].<ref>{{cite journal | vauthors = Yang E, Hwang I, Ji SC, Kim J, Lee S | title = Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers | journal = CPT | volume = 13 | issue = 12 | pages = 2150–2158 | date = December 2024 | pmid = 39268835 | doi = 10.1002/psp4.13228 | pmc = 11646930 }}</ref><ref>{{cite journal | vauthors = Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC | title = Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease | journal = Expert Opinion on Drug Metabolism & Toxicology | pages = 1–16 | date = September 2024 | pmid = 39189409 | doi = 10.1080/17425255.2024.2397433 }}</ref> In April 2024, it was approved for use in South Korea for the treatment of erosive ] (GERD).<ref>{{cite journal | vauthors = Blair HA | title = Zastaprazan: First Approval | journal = Drugs | volume = 84 | issue = 7 | pages = 863–866 | date = July 2024 | pmid = 38916840 | doi = 10.1007/s40265-024-02057-w }}</ref> In addition, it is in Phase III clinical trials for ] and ].<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800044958 | title = Zastaprazan | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref>


==References== == References ==
{{reflist}} {{reflist}}

{{Drugs for peptic ulcer and GORD}}


] ]
] ]
] ]
]
]



{{gastrointestinal-drug-stub}} {{gastrointestinal-drug-stub}}

Latest revision as of 13:57, 31 December 2024

Pharmaceutical compound
Zastaprazan
Clinical data
Trade namesJaqbo
Other namesJP-1366
Legal status
Legal status
  • Rx in South Korea
Identifiers
IUPAC name
  • azetidin-1-yl--2,3-dimethylimidazopyridin-6-yl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H26N4O
Molar mass362.477 g·mol
3D model (JSmol)
SMILES
  • CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4
InChI
  • InChI=1S/C22H26N4O/c1-14-7-5-8-15(2)19(14)12-23-20-11-18(22(27)25-9-6-10-25)13-26-17(4)16(3)24-21(20)26/h5,7-8,11,13,23H,6,9-10,12H2,1-4H3
  • Key:FEQFUBYYZYQTOJ-UHFFFAOYSA-N

Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker. In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.

References

  1. Yang E, Hwang I, Ji SC, Kim J, Lee S (December 2024). "Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers". CPT. 13 (12): 2150–2158. doi:10.1002/psp4.13228. PMC 11646930. PMID 39268835.
  2. Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC (September 2024). "Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease". Expert Opinion on Drug Metabolism & Toxicology: 1–16. doi:10.1080/17425255.2024.2397433. PMID 39189409.
  3. Blair HA (July 2024). "Zastaprazan: First Approval". Drugs. 84 (7): 863–866. doi:10.1007/s40265-024-02057-w. PMID 38916840.
  4. "Zastaprazan". AdisInsight. Springer Nature Switzerland AG.
Drugs for peptic ulcer and GERD/GORD (A02B)
H2 antagonists ("-tidine")
Prostaglandins (E)/
analogues ("-prost-")
Proton-pump inhibitors
("-prazole")
Potassium-competitive
acid blockers ("-prazan")
Others
Combinations


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: